On August 2, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, reported that it will host a conference call and webcast to provide a business and clinical update on Wednesday, August 9, 2023 at 4:30 p.m. EDT (Press release, Cue Biopharma, AUG 2, 2023, View Source [SID1234633670]). Live and archived versions of the event can be accessed via the Company’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will provide a clinical update from its ongoing Phase 1 trial evaluating CUE-101, the company’s lead interleukin 2 (IL-2)-based biologic from the CUE-100 series, in combination with pembrolizumab (KEYTRUDA) for patients with recurrent/metastatic HPV+ head and neck cancer, as well as clinical progress from the Phase 1 monotherapy dose escalation trial of the company’s second clinical drug asset, CUE-102, for the treatment of patients with Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancers. Additional clinical, pipeline and business updates will also be addressed.
Webcast Details
Wednesday, August 9 at 4:30 p.m. EDT
Investors: 1-888-886-7786
International: 1-416-764-8658
Conference ID: 92073568
Request a return call via the Call me link: View Source;
Participants can use the guest dial-in numbers above and be answered by an operator or click the Call me link for instant telephone access. The link will be active 15 minutes prior to the scheduled start time.
Webcast: View Source;tp_key=38376b8c08